AC Immune (ACIU) News Today $3.52 -0.07 (-1.95%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$3.56 +0.04 (+1.14%) As of 10/8/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACIU Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period AC Immune's (ACIU) "Sell (D-)" Rating Reiterated at Weiss RatingsOctober 8 at 1:21 PM | marketbeat.comA Look at AC Immune’s (NasdaqGM:ACIU) Valuation After New Alzheimer’s Immunotherapy Trial ResultsOctober 7 at 1:45 PM | finance.yahoo.comAC Immune (NASDAQ:ACIU) Trading 3% Higher - Should You Buy?October 2, 2025 | marketbeat.comAC Immune announces publication of results on ACI-35.030 in eBioMedicineSeptember 25, 2025 | msn.comPeer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicineSeptember 25, 2025 | finance.yahoo.comLeerink Partners Reaffirms Their Buy Rating on AC Immune SA (ACIU)September 14, 2025 | theglobeandmail.comAC Immune (NASDAQ:ACIU) Rating Increased to Hold at Zacks ResearchSeptember 13, 2025 | marketbeat.comAC Immune (NASDAQ:ACIU) Given "Buy" Rating at BTIG ResearchSeptember 10, 2025 | marketbeat.comAC Immune SA: Strategic Focus and Innovative Platforms Drive Buy Rating Amid Promising Immunotherapy DevelopmentsSeptember 8, 2025 | tipranks.comBVF Inc. IL Purchases 300,000 Shares of AC Immune $ACIUSeptember 5, 2025 | marketbeat.comAC Immune SA Announces Strategic Focus and Workforce ReductionSeptember 4, 2025 | tipranks.comAC Immune SA: AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash RunwaySeptember 4, 2025 | finanznachrichten.deAC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash RunwaySeptember 4, 2025 | finance.yahoo.comAC Immune SA Announces Strategic Pipeline Focus and Workforce Reduction to Extend Cash RunwaySeptember 4, 2025 | quiverquant.comQAC Immune (NASDAQ:ACIU) Trading Down 3.7% - Time to Sell?August 27, 2025 | marketbeat.comFY2025 EPS Estimates for AC Immune Lowered by HC WainwrightAugust 9, 2025 | marketbeat.comQ3 Earnings Estimate for AC Immune Issued By Leerink PartnrsAugust 9, 2025 | marketbeat.comAC Immune Reports Q2 2025 Financial ProgressAugust 8, 2025 | tipranks.comFY2027 EPS Estimates for AC Immune Reduced by HC WainwrightAugust 8, 2025 | marketbeat.comLeerink Partnrs Weighs in on AC Immune FY2027 EarningsAugust 8, 2025 | marketbeat.comAC Immune (NASDAQ:ACIU) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPSAugust 6, 2025 | marketbeat.comAC Immune SA Reports Increased Losses in Mid-2025 Financial ResultsAugust 5, 2025 | tipranks.comAC Immune SA Reports Q2 2025 Financial Results and Advancements in Neurodegenerative Disease TherapiesAugust 5, 2025 | quiverquant.comQAC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateAugust 5, 2025 | globenewswire.comAC Immune (ACIU) Expected to Announce Quarterly Earnings on TuesdayJuly 30, 2025 | marketbeat.comLeerink Partnrs Raises Earnings Estimates for AC ImmuneJuly 14, 2025 | marketbeat.comAC Immune (NASDAQ:ACIU) Shares Down 3.9% - What's Next?July 7, 2025 | marketbeat.comACIU AC Immune SA - Seeking AlphaJune 29, 2025 | seekingalpha.comAC Immune SA (ACIU) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comAC Immune Ltd Analysis & Opinion (ACIU) - Investing.comJune 25, 2025 | investing.comNorthern Trust Corp Makes New Investment in AC Immune SA (NASDAQ:ACIU)May 30, 2025 | marketbeat.comAC Immune SA Announces Board Changes Ahead of June 2025 AGMMay 19, 2025 | tipranks.comAC Immune (NASDAQ:ACIU) Upgraded to Buy at StockNews.comMay 15, 2025 | marketbeat.comAC Immune (ACIU) to Release Earnings on MondayMay 7, 2025 | marketbeat.comEquities Analysts Issue Forecasts for AC Immune Q2 EarningsMay 6, 2025 | marketbeat.comAC Immune SA Reports Q1 2025 Financial Results and Clinical Advancements in Neurodegenerative Disease TherapiesMay 1, 2025 | nasdaq.comAC Immune SA: AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateMay 1, 2025 | finanznachrichten.deAC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateApril 30, 2025 | globenewswire.comIndividual investors in AC Immune SA (NASDAQ:ACIU) are its biggest bettors, and their bets paid off as stock gained 11% last weekApril 26, 2025 | finance.yahoo.comQ2 Earnings Forecast for AC Immune Issued By Leerink PartnrsApril 18, 2025 | marketbeat.comQ1 Earnings Forecast for AC Immune Issued By Leerink PartnrsApril 17, 2025 | marketbeat.comAC Immune (NASDAQ:ACIU) Receives Buy Rating from HC WainwrightApril 5, 2025 | marketbeat.comAC Immune SA: Promising Phase 2 Results and Positive Outlook Drive Buy RatingApril 4, 2025 | tipranks.comAC Immune’s Strategic Advances and Financial HighlightsApril 2, 2025 | tipranks.comAC Immune announces additional data from Phase 2 study of VacSYn clinical trialApril 2, 2025 | markets.businessinsider.comAC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseApril 2, 2025 | markets.businessinsider.comAC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's DiseaseApril 2, 2025 | globenewswire.comShort Interest in AC Immune SA (NASDAQ:ACIU) Rises By 23.9%April 1, 2025 | marketbeat.comAC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025March 25, 2025 | globenewswire.comPromising Developments in AC Immune SA’s ACI-7104 Program Drive Buy RatingMarch 18, 2025 | tipranks.com Get AC Immune News Delivered to You Automatically Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACIU Media Mentions By Week ACIU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACIU News Sentiment▼0.700.63▲Average Medical News Sentiment ACIU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACIU Articles This Week▼41▲ACIU Articles Average Week Get the Latest News and Ratings for ACIU and Related Stocks Enter your email address to receive the latest news and analysts' ratings for AC Immune and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Structure Therapeutics News Today Harmony Biosciences News Today Phibro Animal Health News Today Schrodinger News Today Aurinia Pharmaceuticals News Today Avadel Pharmaceuticals News Today Janux Therapeutics News Today Evotec News Today Arcus Biosciences News Today Stoke Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACIU) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
